Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal TJ Mitchell, S Turajlic, A Rowan, D Nicol, JHR Farmery, T O’Brien, ... Cell 173 (3), 611-623. e17, 2018 | 461 | 2018 |
The mutational landscape of normal human endometrial epithelium L Moore, D Leongamornlert, THH Coorens, MA Sanders, P Ellis, ... Nature 580 (7805), 640-646, 2020 | 381 | 2020 |
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition B Rodriguez-Martin, EG Alvarez, A Baez-Ortega, J Zamora, F Supek, ... Nature genetics 52 (3), 306-319, 2020 | 309 | 2020 |
Genomic landscape and chronological reconstruction of driver events in multiple myeloma F Maura, N Bolli, N Angelopoulos, KJ Dawson, D Leongamornlert, ... Nature communications 10 (1), 3835, 2019 | 239 | 2019 |
Genomic patterns of progression in smoldering multiple myeloma N Bolli, F Maura, S Minvielle, D Gloznik, R Szalat, A Fullam, ... Nature communications 9 (1), 3363, 2018 | 185 | 2018 |
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups N Bolli, G Biancon, M Moarii, S Gimondi, Y Li, C de Philippis, F Maura, ... Leukemia 32 (12), 2604-2616, 2018 | 182 | 2018 |
A practical guide for mutational signature analysis in hematological malignancies F Maura, A Degasperi, F Nadeu, D Leongamornlert, H Davies, L Moore, ... Nature communications 10 (1), 2969, 2019 | 161 | 2019 |
Timing the initiation of multiple myeloma EH Rustad, V Yellapantula, D Leongamornlert, N Bolli, G Ledergor, ... Nature communications 11 (1), 1917, 2020 | 130 | 2020 |
Autoimmune cytopenias in chronic lymphocytic leukemia C Visco, W Barcellini, F Maura, A Neri, A Cortelezzi, F Rodeghiero American journal of hematology 89 (11), 1055-1062, 2014 | 129 | 2014 |
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines F Maura, M Petljak, M Lionetti, I Cifola, W Liang, E Pinatel, LB Alexandrov, ... Leukemia 32 (4), 1043-1047, 2018 | 96 | 2018 |
Revealing the impact of structural variants in multiple myeloma EH Rustad, VD Yellapantula, D Glodzik, KH Maclachlan, B Diamond, ... Blood cancer discovery 1 (3), 258-273, 2020 | 89 | 2020 |
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: a comparison of cellular, cytogenetic, molecular, and clinical features F Morabito, L Mosca, G Cutrona, L Agnelli, G Tuana, M Ferracin, B Zagatti, ... Clinical cancer research 19 (21), 5890-5900, 2013 | 86 | 2013 |
COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ... Blood cancer discovery 1 (3), 234-243, 2020 | 80 | 2020 |
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities B Oben, G Froyen, KH Maclachlan, D Leongamornlert, F Abascal, ... Nature communications 12 (1), 1861, 2021 | 74 | 2021 |
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma EM Boyle, S Deshpande, R Tytarenko, C Ashby, Y Wang, MA Bauer, ... Nature communications 12 (1), 293, 2021 | 72 | 2021 |
High‐throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications M Lionetti, S Fabris, G Cutrona, L Agnelli, C Ciardullo, S Matis, G Ciceri, ... British journal of haematology 165 (5), 629-639, 2014 | 66 | 2014 |
Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the … O Landgren, M Hultcrantz, B Diamond, AM Lesokhin, S Mailankody, ... JAMA oncology 7 (6), 862-868, 2021 | 65 | 2021 |
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia F Nadeu, R Royo, R Massoni-Badosa, H Playa-Albinyana, B Garcia-Torre, ... Nature medicine 28 (8), 1662-1671, 2022 | 63 | 2022 |
An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures G Collord, P Tarpey, N Kurbatova, I Martincorena, S Moran, M Castro, ... Scientific reports 8 (1), 13537, 2018 | 56 | 2018 |
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial B Diamond, N Korde, AM Lesokhin, EL Smith, U Shah, S Mailankody, ... The Lancet Haematology 8 (6), e422-e432, 2021 | 54 | 2021 |